Ask AI
ELCC 2025 Highlights

CME

Highlights of the 2025 European Lung Cancer Congress

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: May 27, 2025

Expiration: November 26, 2025

Activity

Progress
1 2
Course Completed

References

  1. Lu S, Kato T, Dong X, et al. Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC. N Engl J Med. 2024;391:585-597.
  2. Osimertinib [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2024.
  3. Ramalingam SS, Özgüroglu M, Ahn M-J, et al. Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable (UR) stage III EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC): Updated overall survival (OS) analysis from the LAURA study. Presented at: European Lung Cancer Congress; March 26-29, 2025. Abstract LBA4.
  4. Zhang Y-L, Yuan J-Q, Wang K-F, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7:78985-78993.
  5. Harrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol. 2020;61:167-179.
  6. Yang JC-H, Kim YJ, Lee S-H, et al. Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: Final overall survival (OS) from the phase III MARIPOSA study. Presented at: European Lung Cancer Congress; March 26-29, 2025. Abstract 4O.
  7. Cho BC, Lu S, Felip E, et al. Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC. N Engl J Med. 2024;391:1486-1498.
  8. Amivantamab-vmjw [prescribing information]. Horsham, PA: Janssen Biotech, Inc.; 2025.
  9. Amivantamab-vmjw [summary of product characteristics]. Leiden, The Netherlands: Janssen Biologics; 2025.
  10. Lazertinib [prescribing information]. Horsham, PA: Janssen Biotech, Inc.; 2024.
  11. Lazertinib [summary of product characteristics]. Latina, Italy: Janssen Cilag; 2025.
  12. Tozuka T, Noro R, Mizutani H, et al. Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-mutant non-small cell lung cancer. Lung Cancer. 2024;191:107540.
  13. Girard N, Li W, Spira A, et al. Preventing moderate to severe dermatologic adverse events in first-line EGFR-mutant advanced NSCLC treated with amivantamab plus lazertinib: Early success of the COCOON trial. Presented at: European Lung Cancer Congress; March 26-29, 2025. Abstract 10MO.
  14. Spira AI, Paz-Ares L, Han J-Y, et al. Preventing infusion-related reactions with intravenous amivantamab—results from SKIPPirr, a phase 2 study: a brief report. J Thorac Oncol. 2025;[Epub ahead of print].
  15. Lim SM, Tan J-L, Mourão Dias J, et al. Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study. Presented at: 2024 Annual Meeting of the American Society of Clinical Oncology; May 31-June 4, 2024. Abstract LBA8612.
  16. Planchard D, Jänne PA, Cheng Y, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med. 2023;389:1935-1948.
  17. Hendriks LE, Kerr KM, Menis J, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:339-357.
  18. Bazhenova L, Ismaila N, Abu Rous F, et al. Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO Living Guideline, Version 2024.2. J Clin Oncol. 2024;42:e72-86.
  19. Lee J, Piotrowska Z, Soo R, et al. Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer. Ther Adv Med Oncol. 2022;14:17588359221144099.
  20. Okajima D, Yasuda S, Maejima T, et al. Datopotamab deruxtecan, a novel TROP2-directed antibody–drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol Cancer Ther. 2021;20:2329-2340.
  21. Ahn M-J, Tanaka K, Paz-Ares L, et al. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 Study. J Clin Oncol. 2025;43:260-272.
  22. Sands J, Ahn MJ, Lisberg A, et al. Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: results from the phase II TROPION-Lung05 Study. J Clin Oncol. 2025;43:1254-1265.
  23. Le X, Henriks L, Morabito A, et al. Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD. Presented at: European Lung Cancer Congress; March 26-29, 2025. Abstract 1O.
  24. Heist RS, Sands J, Bardia A, et al. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev. 2024;125:102720.
  25. Meric-Bernstam F, Bardia A, Bossi P,  et al. Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis. Oncologist. 2025;30:oyaf031.
  26. Leonetti A, Sharma S, Minari R, et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121:725-377.
  27. Piotrowska Z, Ahn M-J, Pang YK, et al. LBA53 ELIOS: A multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib. Presented at: European Society for Medical Oncology Congress; September 9-13, 2022. Abstract LBA53.
  28. Chmielecki J, Gray JE, Cheng Y, et al. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nat Commun. 2023;14:1070.
  29. Yu HA, Kerr K, Rolfo CD, et al. Detection of MET amplification (METamp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib. Presented at: Annual Meeting of the American Society of Clinical Oncology; June 2-6, 2023. Abstract 9074.
  30. Ahn M-J, De Marinis F, Bonanno L, et al. MET biomarker-based preliminary efficacy analysis in SAVANNAH: savolitinib + osimertinib in EGFRm NSCLC post-osimertinib. Presented at: The International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer; August 6-9, 2022. Abstract EP08.02-140.
  31. Ahn MJ, Bonanno L, Cheng S, et al. SAVANNAH: Savolitinib (savo) + osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and METoverexpression (OverExp) and/or amplification (Amp) following progressive disease (PD) on osi. Presented at: European Lung Cancer Congress; March 26-29, 2025. Abstract 2O.
  32. Nishio M, Kato T, Toyozawa R, et al. Management of peripheral edema in patients with MET exon 14-mutated non-small cell lung cancer treated with small molecule MET inhibitors. Target Oncol. 2022;17:597-604.
  33. Riudavets M, Sullivan I, Abdayem P, et al. Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations. ESMO Open. 2021;6:100260.
  34. Remon J, Hendriks LEL, Cardona AF, et al. EGFR exon 20 insertions in advanced non-small cell lung cancer: a new history begins. Cancer Treat Rev. 2020;90:102105.
  35. Goto K, Goto Y, Kubo T, et al. Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial. J Clin Oncol. 2023;41:4852-4863.
  36. Li BT, Smit EF, Goto Y, et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med. 2022;386:241-251.
  37. Loong HHF, Daniele G, Yang T-Y, et al. Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2 exon20 insertion (ex20ins) mutations treated in a phase I study with BAY 2927088. Presented at: European Society for Medical Oncology Congress; October 20-24, 2023. Abstract 1320MO.
  38. Girard N, Kim TM, Kim HR, et al. Safety and anti-tumor activity of BAY 2927088 in patients with HER2-mutant NSCLC: results from an expansion cohort of the SOHO-01 phase I/II study. Presented at: Annual Meeting of the American Society of Clinical Oncology; May 31-June 4, 2024. Abstract LBA8598.
  39. Goto K, Brase JC, Xu J, et al. SOHO-02: Phase III trial of BAY 2927088 in patients with locally advanced or metastatic NSCLC with HER2-activating mutations. Presented at: International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer; September 7-10, 2024. Abstract EP.12H.08.
  40. Girard N, Loong HHF, Goh B-C, et al. Phase I/II SOHO-01 study of BAY 2927088 in patients with previously treated HER2-mutant NSCLC: safety and efficacy results from 2 expansion cohorts. Presented at: European Lung Cancer Congress; March 26-29, 2025. Abstract 3O.
  41. Rugo HS, Crossno CL, Gesthalter YB, et al. Real-world perspectives and practices for pneumonitis/interstitial lung disease associated with trastuzumab deruxtecan use in human epidermal growth factor receptor 2-expressing metastatic breast cancer. JCO Oncol Pract. 2023;19:539-546.
  42. Garassino MC, Baramidze A, Kilickap S, et al. Continued cemiplimab with addition of chemotherapy beyond progression in patients with advanced NSCLC on 1L cemiplimab monotherapy: 5-year outcomes of EMPOWER-Lung 1. Presented at: European Lung Cancer Congress; March 26-29, 2025. Abstract 16P.
  43. Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397:592-604.
  44. Özgüroğlu M, Kilickap S, Sezer A, et al. First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24:989-1001.
  45. Bersanelli M, Buti S, Giannarelli D, et al. Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study. Lung Cancer. 2020;150:123-131.